India is preparing to launch low-cost generic versions of semaglutide-based drugs like Ozempic and Wegovy as patents expire in 2026. With pharma companies and regulators aligned, these generics could dramatically reduce costs, expand access to obesity and diabetes treatments, and reshape India’s weight-loss drug market for millions of patients.
Show moreStay Ahead – Explore Now! India Inc Bets On Empathy-Driven Benefits To Retain Talent
Copyright 2024 WOWNEWS 24x7. All rights reserved. The WOWNEWS 24x7 is not responsible for the content of external sites. Read about our approach to external linking.
Powered By Just Imagine
